Ipilimumab in patients with melanoma and autoimmune disease

Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyi, Chrisann, Carvajal, Richard D, Wolchok, Jedd D, Postow, Michael A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207313/
https://www.ncbi.nlm.nih.gov/pubmed/25349698
http://dx.doi.org/10.1186/s40425-014-0035-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207313/
https://www.ncbi.nlm.nih.gov/pubmed/25349698
http://dx.doi.org/10.1186/s40425-014-0035-z

Ejemplares similares